Development
Silo Pharma, Inc.
SILO
$0.5983
-$0.0411-6.43%
NASDAQ
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | 0.00% | |||
| Cost of Revenue | 0.00% | 0.00% | |||
| Gross Profit | 0.00% | 0.00% | |||
| SG&A Expenses | -38.50% | 62.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -30.15% | 37.92% | |||
| Operating Income | 30.64% | -38.77% | |||
| Income Before Tax | 34.83% | -11.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 34.83% | -11.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 34.83% | -11.76% | |||
| EBIT | 30.64% | -38.77% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 33.87% | -11.96% | |||
| Normalized Basic EPS | 33.72% | -36.15% | |||
| EPS Diluted | 33.87% | -11.96% | |||
| Normalized Diluted EPS | 33.72% | -36.15% | |||
| Average Basic Shares Outstanding | -1.43% | -0.16% | |||
| Average Diluted Shares Outstanding | -1.43% | -0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||